Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.

Apoptosis / drug effects Binding Sites Cell Line Cell Survival / drug effects Drug Evaluation, Preclinical Glucose Transporter Type 1 / antagonists & inhibitors Histone Deacetylase Inhibitors / chemical synthesis Histone Deacetylases / metabolism Humans Molecular Docking Simulation Protein Isoforms / antagonists & inhibitors Repressor Proteins / antagonists & inhibitors Structure-Activity Relationship Thiazolidinediones / chemistry
Docking GLUT HDAC Leukemia N-substituted thiazolidinediones

Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
07 2020
Historique:
received: 31 03 2020
revised: 11 05 2020
accepted: 11 05 2020
pubmed: 24 5 2020
medline: 2 3 2021
entrez: 24 5 2020
Statut: ppublish

Résumé

Epigenetics plays a fundamental role in cancer progression, and developing agents that regulate epigenetics is crucial for cancer management. Among Class I and Class II HDACs, HDAC8 is one of the essential epigenetic players in cancer progression. Therefore, we designed, synthesized, purified, and structurally characterized novel compounds containing N-substituted TZD (P1-P25). Cell viability assay of all compounds on leukemic cell lines (CEM, K562, and KCL22) showed the cytotoxic potential of P8, P9, P10, P12, P19, and P25. In-vitro screening of different HDACs isoforms revealed that P19 was the most potent and selective inhibitor for HDAC8 (IC

Identifiants

DOI: 10.1016/j.bioorg.2020.103934 PMID: 32446120 PMC: PMC7302971
pubmed: 32446120
pii: S0045-2068(20)30740-9
doi: 10.1016/j.bioorg.2020.103934
pmc: PMC7302971
mid: NIHMS1596839
pii:
doi:

Substances chimiques

Glucose Transporter Type 1 0
Histone Deacetylase Inhibitors 0
Protein Isoforms 0
Repressor Proteins 0
Thiazolidinediones 0
HDAC8 protein, human EC 3.5.1.98
Histone Deacetylases EC 3.5.1.98

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

103934

Subventions

Organisme : NIMHD NIH HHS
ID : U54 MD007592
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None.

Références

ChemMedChem. 2014 Mar;9(3):657-64
pubmed: 24403121
Future Med Chem. 2017 Dec;9(18):2211-2237
pubmed: 29182018
Biometrics. 1978 Sep;34(3):357-65
pubmed: 719119
Anticancer Agents Med Chem. 2017;17(4):524-541
pubmed: 27291250
Eur J Med Chem. 2019 Dec 15;184:111756
pubmed: 31630054
J Enzyme Inhib Med Chem. 2018 Dec;33(1):714-721
pubmed: 29616828
Regul Toxicol Pharmacol. 2015 Feb;71(1):52-62
pubmed: 25460032
Int J Oncol. 2015 Nov;47(5):1819-28
pubmed: 26412386
Molecules. 2015 Mar 02;20(3):3898-941
pubmed: 25738536
Leukemia. 2011 Feb;25(2):226-35
pubmed: 21116282
Anticancer Agents Med Chem. 2014;14(6):872-83
pubmed: 24875128
Bioorg Med Chem. 2011 Aug 1;19(15):4626-34
pubmed: 21723733
Bioorg Med Chem Lett. 2016 Feb 1;26(3):1005-1010
pubmed: 26725026
Future Med Chem. 2016 Sep;8(13):1609-34
pubmed: 27572818
BMC Pharmacol Toxicol. 2016 Jul 21;17(1):32
pubmed: 27443303
Bioorg Med Chem Lett. 2010 May 15;20(10):3138-41
pubmed: 20392637
Antioxid Redox Signal. 2015 Jul 1;23(1):99-126
pubmed: 24382114
Redox Biol. 2019 Jan;20:60-67
pubmed: 30292946
Trends Pharmacol Sci. 2015 Jul;36(7):481-92
pubmed: 26013035
J Struct Biol. 2016 Sep;195(3):373-378
pubmed: 27374062
Curr Cancer Drug Targets. 2011 Sep;11(7):882-93
pubmed: 21762078
J Med Chem. 2018 Nov 21;61(22):10000-10016
pubmed: 30347148
J Biol Chem. 2010 Mar 26;285(13):9780-91
pubmed: 20093366
Mol Endocrinol. 2009 Mar;23(3):388-401
pubmed: 19106193
Eur J Med Chem. 2019 Feb 15;164:214-240
pubmed: 30594678
J Biomol Struct Dyn. 2020 Apr;38(6):1751-1760
pubmed: 31057077
Cell Physiol Biochem. 2003;13(3):123-34
pubmed: 12876383
Expert Opin Ther Pat. 2017 May;27(5):621-636
pubmed: 28033734
Med Chem. 2013 Dec;9(8):1051-7
pubmed: 23521008
PLoS One. 2017 Jan 6;12(1):e0169128
pubmed: 28060870
Sci Rep. 2017 Jul 24;7(1):6197
pubmed: 28740135
Expert Opin Investig Drugs. 2009 Nov;18(11):1605-17
pubmed: 19780707
Sci Rep. 2017 Mar 03;7:42717
pubmed: 28256516
J Chem Inf Model. 2015 Apr 27;55(4):861-71
pubmed: 25757142
J Med Chem. 2003 Nov 20;46(24):5097-116
pubmed: 14613312
Bioorg Chem. 2016 Aug;67:139-47
pubmed: 27388635
Biol Chem. 2019 May 27;400(6):733-743
pubmed: 30521473
Eur J Med Chem. 2010 Oct;45(10):4539-44
pubmed: 20667627
Bioorg Chem. 2020 Jan;95:103522
pubmed: 31901516
Front Oncol. 2018 Mar 29;8:92
pubmed: 29651407
Sci Rep. 2019 Sep 12;9(1):13187
pubmed: 31515509
Br J Cancer. 2016 Mar 15;114(6):605-11
pubmed: 26908329
Bioorg Med Chem Lett. 2011 Dec 15;21(24):7509-12
pubmed: 22036991
Anticancer Agents Med Chem. 2017;17(1):67-74
pubmed: 27141880
Curr Opin Oncol. 2012 Nov;24(6):650-4
pubmed: 22913968
Cancers (Basel). 2018 Feb 17;10(2):
pubmed: 29462961
Sci Rep. 2016 Apr 14;6:24240
pubmed: 27074918
Curr Cell Biochem. 2011;1(1):1-14
pubmed: 27042697
ChemMedChem. 2016 Jun 6;11(11):1117-21
pubmed: 27218427
Acta Crystallogr C Struct Chem. 2018 Feb 01;74(Pt 2):146-151
pubmed: 29400328
Biochim Biophys Acta Gen Subj. 2019 Mar;1863(3):577-585
pubmed: 30611847
SAR QSAR Environ Res. 2008;19(5-6):495-524
pubmed: 18853299
Anticancer Agents Med Chem. 2018;18(11):1551-1562
pubmed: 29683096
J Liposome Res. 2019 Sep;29(3):291-311
pubmed: 30526186
Elife. 2018 Mar 21;7:
pubmed: 29561261
Biochim Biophys Acta. 1997 Feb 21;1324(1):111-9
pubmed: 9059504
Future Med Chem. 2012 Mar;4(4):505-24
pubmed: 22416777
Leukemia. 2008 May;22(5):1026-34
pubmed: 18256683
Pharm Pat Anal. 2018 Nov;7(6):259-276
pubmed: 30632447

Auteurs

Neha Upadhyay (N)

Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, India.

Kalpana Tilekar (K)

Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, India.

Niklas Jänsch (N)

Department of Chemical Engineering and Biotechnology, University of Applied Science, Darmstadt, Germany.

Markus Schweipert (M)

Department of Chemical Engineering and Biotechnology, University of Applied Science, Darmstadt, Germany.

Jessica D Hess (JD)

The Cellular Characterization and Biorepository Core Facility & Border Biomedical Research Centre & Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, USA.

Luca Henze Macias (L)

The Cellular Characterization and Biorepository Core Facility & Border Biomedical Research Centre & Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, USA.

Piotr Mrowka (P)

Department of Biophysics and Human Physiology, Medical University of Warsaw, Chalubinskiego, Warsaw, Poland; Institute of Hematology and Blood Transfusion, Indira Gandhi St., Warsaw, Poland.

Renato J Aguilera (RJ)

The Cellular Characterization and Biorepository Core Facility & Border Biomedical Research Centre & Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, USA.

Jun-Yong Choe (JY)

East Carolina Diabetes and Obesity Institute, East Carolina University, Greenville, NC 27834, USA; Department of Biochemistry and Molecular Biology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.

Franz-Josef Meyer-Almes (FJ)

Department of Chemical Engineering and Biotechnology, University of Applied Science, Darmstadt, Germany. Electronic address: franz-josef.meyer-almes@h-da.de.

C S Ramaa (CS)

Department of Pharmaceutical Chemistry, Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai, India. Electronic address: sinharamaa@yahoo.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › Discovery of novel N-substituted...
questionsmedicales.fr › Phénomènes chimiques › Phénomènes biochimiques › Sites de fixation › Discovery of novel N-substituted...
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Discovery of novel N-substituted...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Survie cellulaire › Discovery of novel N-substituted...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Discovery of novel N-substituted...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Protéines de transport membranaire › Protéines transporteurs de solutés › Transporteurs de glucose par diffusion facilitée › Transporteur de glucose de type 1 › Discovery of novel N-substituted...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de désacétylase d'histone › Discovery of novel N-substituted...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Amidohydrolases › Histone deacetylases › Discovery of novel N-substituted...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Discovery of novel N-substituted...
questionsmedicales.fr › Sciences de l'information › Méthodologies informatiques › Simulation numérique › Simulation de docking moléculaire › Discovery of novel N-substituted...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Isoformes de protéines › Discovery of novel N-substituted...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéines de répression › Discovery of novel N-substituted...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Relation structure-activité › Discovery of novel N-substituted...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Thiazoles › Thiazolidinediones › Discovery of novel N-substituted...